Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
Adding high-fiber meals when you can barely finish half a plate is impractical
Bhasin S, Brito JP, Cunningham GR, et al
A provider reviews your information
This means that the dosing question is not just "how much" but "for how long." A researcher who reaches their goal weight at month 8 needs to consider whether to continue at a maintenance dose, reduce to a lower maintenance level, or taper off with the understanding that some regain is likely
Virta offers just thata tech-forward approach that lowers drug spend for utilizing members while improving member health. Payers want innovative solutions to the chronic disease cost crisis, especially amid the rise in use of GLP-1s